IN8bio presented Phase 1 data on INB-100 at 2025 TCT
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...